Gertjan Rasschaert, Medical Doctor and Consultant specializing in Gastrointestinal Oncology and Gastroenterology at UZ Leuven, shared a post on LinkedIn:

“AZUR-4 is open in 10 centers in Belgium: neoadjuvant immunotherapy in pMMR/MSS CRC.

Thanks MediMix for highlighting our UZ Leuven – KU Leuven trial in progress poster, presented at last month’s American Society of Clinical Oncology (ASCO).

AZUR-4 is a 3:1 randomized phase 2/3 study (NCT06091254) investigating the use of neoadjuvant dostarlimab in combination with capecitabine and oxaliplatin (CAPEOX) compared to CAPEOX alone in previously untreated T4N0 or Stage III mismatch repair proficient (MMRp)/microsatellite stable (MSS) colon cancer.”

More posts featuring Gertjan Rasschaert.

Gertjan Rasschaert: AZUR-4 Trial on Neoadjuvant Immunotherapy in MSS Colon Cancer

“AZUR-4 is open in 10 centers in Belgium: neoadjuvant immunotherapy in pMMR/MSS CRC.

Thanks MediMix for highlighting our UZ Leuven – KU Leuven trial in progress poster, presented at last month’s American Society of Clinical Oncology (ASCO).